Steven M. Klosk

Director
Steven Kiosk, Lisata Board of Directors
Steven M. Klosk, Lisata Board of Directors

Steven M. Klosk joined the Company’s Board in 2014. He is a senior executive with extensive management experience in the life sciences industry. He served as a Director at Cambrex Corporation (NYSE: CBM) from May 2008 through December 2019, until it was acquired by Permira, and then as Director from December 2019 to June 2020. Cambrex is one of the leading providers of active pharmaceutical ingredients, advanced intermediates and finished dosage form products to the branded and generic pharmaceutical markets, where he served as President and Chief Executive Officer from May 2008 through June 2020. In that role he was responsible for all aspects of Cambrex’s global business with manufacturing and R&D facilities in the United States, Canada, Sweden, Italy, Estonia, Germany, and Scotland. Mr. Klosk held other executive positions at Cambrex Corporation, including President, Executive Vice President & COO as well as President, Pharma Business Unit from 2007-2008 where he had full P&L and balance sheet responsibility for four operating units in North America and Europe. Prior to this he was Executive Vice President & COO Cambrex Pharma & Biopharmaceuticals Business Unit from 2003-2007 where he was responsible for managing a highly profitable global business with six operating units in North America and Europe.

Mr. Klosk served on the Board of Directors of Recipharm, a leading pharmaceutical contract development & manufacturing organization since March 2021. He also served as Chairman of the Board of Directors of Formulated Solutions, a topicals contract development & manufacturing organization since September 2021. Mr. Klosk is currently a member of the Board of Directors of BioIVT, a leading biospecimens supplier since October 2021, and serves as a member of the Board of Directors of BIOVECTRA, a small molecule & biologics contract development & manufacturing organization since December 2021. In addition, he serves as a member of the Board of Directors of NJ Bio, an antibody drug conjugate contract research organization since March 2021. 

Mr. Klosk earned a B.S. from Cornell University and a J.D. from New York Law School. The Lisata Board has concluded that Mr. Klosk should continue serving as a Director based on his diversified management experience, particularly in the biopharmaceutical field.